Brought to you by 
Novartis invests in, collaborates with Cellular Biomedicine on CAR-T cancer immunotherapies
26 Oct 2021
Executive Summary
Cellular Biomedicine Group Inc. (CBMG) will manufacture and supply Novartis AG's chimeric antigen receptor T-cell (CAR-T) therapy Kymriah (tisagenlecleucel) in China. Novartis also invests in the company and gets a worldwide license to CBMG's own CAR-T technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis invests in, collaborates with Cellular Biomedicine on CAR-T cancer immunotherapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice